{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-19-016",
    "source_story_id": "tmp-sidebar-radium223-ctdna-prostate-cancer",
    "edition_id": "mp-2026-07-19-morning-0010",
    "edition_url": "https://themachinepress.com/edition/2026-07-19",
    "position": 18,
    "story_type": "ticker",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "A Blood Test Sorts Radium-223 Responders",
    "slug": "a-blood-test-sorts-radium-223-responders",
    "dek": "Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.",
    "summary": "Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.",
    "body_text": "Higher tumor-DNA burden and TP53, PTEN, or cell-cycle alterations were associated with worse outcomes, while changes during treatment reflected disease course. The study proposes a biomarker for selection and monitoring; it does not make the test a validated standard of care.",
    "why_it_matters": "Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.",
    "limitations": [
      "The study proposes a biomarker for selection and monitoring; it does not make the test a validated standard of care."
    ],
    "importance": 7,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-19-016/a-blood-test-sorts-radium-223-responders",
    "json_url": "https://themachinepress.com/story/mp-2026-07-19-016.json",
    "first_published_at": "2026-07-19T09:00:00.000-04:00",
    "modified_at": "2026-07-19T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-19-016-001",
        "text": "Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.",
        "source_ids": [
          "source-2026-07-19-018"
        ],
        "qualification": "The study proposes a biomarker for selection and monitoring; it does not make the test a validated standard of care."
      }
    ],
    "source_ids": [
      "source-2026-07-19-018"
    ],
    "tags": [
      "prostate cancer",
      "circulating tumor DNA",
      "radium-223"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-19-018",
      "title": "Society of Nuclear Medicine and Molecular Imaging: Radium-223 ctDNA",
      "publisher": "Society of Nuclear Medicine and Molecular Imaging",
      "url": "https://snmmi.org/Web/News/Articles/DNA-Blood-Test-Improves-Patient-Selection-for-Radiopharmaceutical-Therapy-in-Prostate-Cancer--",
      "canonical_url": "https://snmmi.org/Web/News/Articles/DNA-Blood-Test-Improves-Patient-Selection-for-Radiopharmaceutical-Therapy-in-Prostate-Cancer--",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": null,
      "accessed_at": "2026-07-19T08:27:22.202-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-19-016-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "A Blood Test Sorts Radium-223 Responders",
    "publisher": "The Machine Press",
    "published_at": "2026-07-19T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-19-016/a-blood-test-sorts-radium-223-responders"
  }
}